Literature DB >> 18607850

Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.

Søren Astrup Jensen1, Ben Vainer, Caroline Janet Witton, Jan Trøst Jørgensen, Jens Benn Sørensen.   

Abstract

BACKGROUND: Most human cancer cells have structural aberrations of chromosomal regions leading to loss or gain of gene specific alleles. This study aimed to assess the range of gene copies per nucleus of thymidylate synthase (TYMS), thymidine phosphorylase (TP) and dihydrofolate reductase (DHFR) in colorectal cancer, and to evaluate its prognostic significance following adjuvant chemotherapy, since these enzymes are closely related to efficacy of 5-fluorouracil (5FU). PATIENTS AND METHODS: Consecutive patients (n = 314), who were completely resected for colorectal cancer stages II-IV and adjuvantly treated with 5-FU were retrospectively evaluated. Paraffin embedded tumor specimens were assessed for gene copies per nucleus of TYMS, TP and DHFR by fluorescence in situ hybridisation (FISH) using specific peptide nucleic acid probes. Outcome according to gene copies per nucleus above and below the median were compared. Also TYMS expression, assessed by immunohistochemistry, was associated with TYMS copies per nucleus.
RESULTS: The number of gene copies per nucleus were 1.7 (0.7-2.8), 1.8 (0.9-3.1) and 1.8 (1.1-2.7) median (range) for TYMS, TP and DHFR, respectively. TYMS expression was directly associated with TYMS genes per nucleus (p = 0.05). Cox multivariate analysis, adjusted for the prognostic impact of disease stage, vascular tumor invasion, and bowel obstruction at resection, revealed that high TYMS gene copy number was associated with significantly higher risk of recurrence (HR = 1.6; 95%CI 1.1-2.2; p = 0.02) and death (HR = 1.6; 95%CI 1.1-2.3; p = 0.01). No significant differences in outcome appeared according to TP and DHFR gene ratios.
CONCLUSION: Aberration of TYMS gene is of significance to expression of TYMS, which may influence the biology and 5-FU sensitivity of colorectal cancer. This may be utilized in the allocation of patients for treatment approaches and for decision on follow-up programs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18607850     DOI: 10.1080/02841860801942158

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  12 in total

1.  Genomic imbalances in esophageal carcinoma cell lines involve Wnt pathway genes.

Authors:  Jacqueline Brown; Hannelie Bothma; Robin Veale; Pascale Willem
Journal:  World J Gastroenterol       Date:  2011-06-28       Impact factor: 5.742

2.  Thymidylate synthase predicts poor response to pemetrexed chemotherapy in patients with advanced breast cancer.

Authors:  Fei Shan; Yu-Lin Liu; Qiang Wang; Yan-Long Shi
Journal:  Oncol Lett       Date:  2018-06-15       Impact factor: 2.967

3.  PharmGKB summary: fluoropyrimidine pathways.

Authors:  Caroline F Thorn; Sharon Marsh; Michelle Whirl Carrillo; Howard L McLeod; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-04       Impact factor: 2.089

4.  Screening the pathogenic genes and pathways related to DMBA (7,12-dimethylbenz[a]anthracene)-induced transformation of hamster oral mucosa from precancerous lesions to squamous cell carcinoma.

Authors:  Dan Chen; Kai Yang; Jie Mei; Guodong Zhang; Xiaoqiang Lv; Li Xiang
Journal:  Oncol Lett       Date:  2011-04-26       Impact factor: 2.967

5.  Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis.

Authors:  Kohei Shigeta; Yoshiyuki Ishii; Hirotoshi Hasegawa; Koji Okabayashi; Yuko Kitagawa
Journal:  World J Surg       Date:  2014-12       Impact factor: 3.352

6.  Thymidine phosphorylase mRNA expression may be a predictor of response to post-operative adjuvant chemotherapy with S-1 in patients with stage III colorectal cancer.

Authors:  Masaichi Ogawa; Michiaki Watanabe; Yoshinobu Mitsuyama; Tadashi Anan; Masahisa Ohkuma; Tetsuya Kobayashi; Ken Eto; Katsuhiko Yanaga
Journal:  Oncol Lett       Date:  2014-09-29       Impact factor: 2.967

7.  Thymidine phosphorylase expression and prognosis in colorectal cancer treated with 5-fluorouracil-based chemotherapy: A meta-analysis.

Authors:  Jia Che; Lun Pan; Xiangling Yang; Zhiting Liu; Lanlan Huang; Chuangyu Wen; Aihua Lin; Huanliang Liu
Journal:  Mol Clin Oncol       Date:  2017-10-03

8.  A Pilot Study of the Predictive Potential of Chemosensitivity and Gene Expression Assays Using Circulating Tumour Cells from Patients with Recurrent Ovarian Cancer.

Authors:  Stefano Guadagni; Marco Clementi; Francesco Masedu; Giammaria Fiorentini; Donatella Sarti; Marcello Deraco; Shigeki Kusamura; Ioannis Papasotiriou; Panagiotis Apostolou; Karl Reinhard Aigner; Giuseppe Zavattieri; Antonietta Rossella Farina; Giuseppe Vizzielli; Giovanni Scambia; Andrew Reay Mackay
Journal:  Int J Mol Sci       Date:  2020-07-07       Impact factor: 5.923

9.  Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.

Authors:  Ioannis Kostopoulos; Vasilios Karavasilis; Maria Karina; Mattheos Bobos; Nikolaos Xiros; George Pentheroudakis; Georgia Kafiri; Pavlos Papakostas; Eleni Vrettou; George Fountzilas
Journal:  BMC Cancer       Date:  2009-09-24       Impact factor: 4.430

10.  Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study.

Authors:  Stefano Guadagni; Giammaria Fiorentini; Michele De Simone; Francesco Masedu; Odisseas Zoras; Andrew Reay Mackay; Donatella Sarti; Ioannis Papasotiriou; Panagiotis Apostolou; Marco Catarci; Marco Clementi; Enrico Ricevuto; Gemma Bruera
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-16       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.